Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 20 | 845 | 21% |
| 2020 | 14 | 850 | 22% |
| 2021 | 19 | 886 | 25% |
| 2022 | 22 | 882 | 27% |
| 2023 | 23 | 822 | 30% |
| 2024 | 21 | 771 | 32% |
| 2025 from claims | – | 764 624–901 | 32% |
| 2026 forecast | – | 781 619–988 | 32% |
| 2027 forecast | – | 790 594–1,054 | 32% |
| 2028 forecast | – | 798 575–1,114 | 33% |
| 2029 forecast | – | 807 560–1,172 | 33% |
| 2030 forecast | – | 817 547–1,228 | 34% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 65% of the cases CMS names in Montana; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% inpatient hospital, 93% hospital outpatient, 2% surgery center. The share outside the hospital has moved −3 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 210 | 10,189+0.7%/yr | +0.7%/yr | 3.1 | 17% | 12,000 in 2030+2.7%/yr |
| Arizona | 76 | 3,870−3.9%/yr | −3.9%/yr | 5.3 | 10% | 4,000 in 2030+0.5%/yr |
| Washington | 69 | 2,999−3.4%/yr | −3.4%/yr | 4.0 | 8% | 2,970 in 2030−0.2%/yr |
| Colorado | 50 | 2,077+0.7%/yr | +0.7%/yr | 4.3 | 23% | 2,720 in 2030+4.6%/yr |
| Oregon | 48 | 1,513−2.3%/yr | −2.3%/yr | 3.7 | 18% | 1,760 in 2030+2.5%/yr |
| Utah | 33 | 1,342−4.3%/yr | −4.3%/yr | 6.2 | 22% | 1,420 in 2030+1%/yr |
| Nevada | 26 | 1,020−3.2%/yr | −3.2%/yr | 3.6 | 24% | 1,090 in 2030+1.2%/yr |
| Idaho | 20 | 897−0.9%/yr | −0.9%/yr | 4.4 | 21% | 1,470 in 2030+8.6%/yr |
| New Mexico | 11 | 541−4.8%/yr | −4.8%/yr | 2.4 | 2% | 560 in 2030+0.7%/yr |
| Alaska | 10 | 375+0.2%/yr | +0.2%/yr | 3.1 | 18% | 410 in 2030+1.5%/yr |
| Hawaii | 7 | 295−2.3%/yr | −2.3%/yr | 2.3 | 0% | 290 in 2030−0.2%/yr |
| Wyoming | 7 | 259−3%/yr | −3%/yr | 2.4 | 18% | 270 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 12 | 680−16%/yr | −16%/yr | 3.60.8× | 7% | 580 in 2030−2.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 7 | 396+6%/yr | +6%/yr | 2.21.0× | 8% | 670 in 2030+9.3%/yr |
| Incontinence, prolapse & sacral neuromodulation | 6 | 325+0.4%/yr | +0.4%/yr | 1.70.9× | 0% | 330 in 2030+0.3%/yr |
| Prostatectomy & nephrectomy | 6 | 211−0.8%/yr | −0.8%/yr | 1.21.1× | 0% | 250 in 2030+2.8%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
Calyxo leads with 67% of company spending on these surgeons in 2025, +43 pts on 2024.
In 2025, 2 companies reported engagement with Montana’s surgeons worth $968 in consulting, speaking, meals and travel tied to these products, about $46 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.